NYSE : BHVN
Biohaven Ltd. — Key statistics
Healthcare · Biotechnology · United States
Last price 15.42 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.33B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.33B |
| Enterprise Value | 2.47B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 151.06M |
| Shares Outstanding | 151.06M |
| Shares Change (YoY) | +38.50% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 10.94% |
| Owned by Institutions (%) | 82.54% |
| Float | 116.59M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 22.93 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.05 |
| Quick Ratio | 2.57 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -90.57% |
| Return on Invested Capital (ROIC) | -122.06% |
| Return on Capital Employed (ROCE) | -242.63% |
| Weighted Average Cost of Capital (WACC) | 19.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.98M |
| Employee Count | 274 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 950,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.20 |
| 52-Week Price Change | -14.85% |
| 50-Day Moving Average | 13.62 |
| 200-Day Moving Average | 12.23 |
| Relative Strength Index (RSI) | 61.06 |
| Average Volume (20 Days) | 3,718,757 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 17.90M |
| Short Previous Month | 20.45M |
| Short % of Shares Out | 11.85% |
| Short % of Float | 15.35% |
| Short Ratio (days to cover) | 7.20 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -487.47M |
| Pretax Income | -541.73M |
| Net Income | -542.68M |
| EBITDA | -478.05M |
| EBIT | -487.47M |
| Earnings Per Share (EPS) | -$3.81 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 161.13M |
| Total Debt | 300.44M |
| Net Cash | -139.32M |
| Net Cash Per Share | -$0.92 |
| Equity (Book Value) | -98.25M |
| Book Value Per Share | -0.65 |
| Working Capital | 128.75M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -472.53M |
| Capital Expenditures | -642,000 |
| Depreciation & Amortization | 9.42M |
| Net Borrowing | n/a |
| Free Cash Flow | -473.17M |
| FCF Per Share | -$3.13 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.50% |
| Shareholder Yield | -38.50% |
| Earnings Yield | -24.71% |
| FCF Yield | -20.31% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $23.33 |
| Price Target Difference | 51.30% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |